David Dingli, MD
Hematology · Rochester, MNNPI 1891769766
Payments from drug & device makers
Across 197 payments — averaging $4629.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$578K
- Novartis$102K
- AstraZeneca$77K
- Sanofi$38K
- Johnson & Johnson$32K
- Karyopharm Therapeutics Inc.$31K
- plus $54K from 15 others
Across 19 payments — averaging $9861.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$161K
- Novartis$26K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 6 | $578,398 |
| Novartis | 51 | $102,366 |
| AstraZeneca | 50 | $77,462 |
| Sanofi | 14 | $37,786 |
| Johnson & Johnson | 33 | $31,761 |
| Karyopharm Therapeutics Inc. | 2 | $30,664 |
| Janssen Scientific Affairs, LLC | 9 | $12,641 |
| Apellis Pharmaceuticals, Inc. | 4 | $6,343 |
| E.r. Squibb & Sons, L.L.C. | 3 | $6,120 |
| Regeneron | 2 | $5,554 |
| Rigel Pharmaceuticals, Inc. | 9 | $5,323 |
| Legend Biotech USA Inc. | 4 | $3,830 |
| Merck | 2 | $3,050 |
| UCB, Inc. | 1 | $3,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,200 |
| GSK | 1 | $1,950 |
| Argenx US, Inc. | 1 | $1,400 |
| Novo Nordisk | 1 | $1,310 |
| UCB SA | 1 | $700 |
| Pfizer | 1 | $150 |
| Janssen Global Services, LLC | 1 | $28 |
How this compares
$912,034 in reported general payments places this provider in the 80th percentile of 111 hematology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Rochester
- Sameer ParikhRochester$44.6M
- Shaji KumarRochester$29.6M
- Lindsey RoekerRochester$9.7M
- Yi LinRochester$9.2M
- Grzegorz NowakowskiRochester$9.1M
- Prashant KapoorRochester$7.6M
- Patrick JohnstonRochester$7.3M
- Mark LitzowRochester$7M
- Jose Villasboas BisnetoRochester$5.5M
- Stephen AnsellRochester$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.